In the space of just a few years, MRM Health has transformed from a challenger in the emerging microbiome therapeutics field to a global forerunner. CEO Sam Possemiers has steered the Belgian company through the rollercoaster of scientific uncertainty and investor skepticism to reach what he calls the “slope of enlightenment.” Now, with late-stage clinical trials ahead and a new important funding round within reach, Possemiers is sharing his lessons-learned with other biotech CEOs.
European biotech is braving another turbulent cycle. IPOs remain scarce, M&A sluggish, and the lack of liquidity is leaving both innovators and Venture Capitalists struggling to raise funds. But new solutions—including stronger secondary markets—could help restore momentum and build a more resilient, thriving European ecosystem.
Just as European biotech began its post-COVID rebound, it now finds itself grappling with a fresh set of global challenges. The re-election of Donald Trump and his ‘America First’ agenda, alongside mounting economic uncertainty and geopolitical shifts have all sent shockwaves through the industry. With shifting capital flows, upended regulatory expectations, and deep insecurity among biotech entrepreneurs, VCs and LPs, we ask: can Europe turn these lemons into lemonade?
A fresh chapter in Flemish healthtech and life sciences has begun with the launch of Biovia: the health innovation cluster resulting from the merger of flanders.bio and MEDVIA. Unveiled at Knowledge for Growth, the flagship annual conference of the Flemish life sciences sector, this new industry-driven organization brings more than 450 members together in one unified ecosystem – cultivating connections and forging a path to a healthier future for people and planet.
The biotechnology sector has always been characterized by long, uncertain timelines. But with increasing scientific, regulatory, and market complexities, biotech development is now taking longer and costing more than ever before. Investors are being faced with a growing gap between initial investment and successful exit, and it’s vital for entrepreneurs to know how to handle this shift.
Drug repurposing describes the process where drugs originally designed for one condition turn out to be highly effective for another. Historically, drug repurposing has often occurred by chance. However, in the era of big data and artificial intelligence, new data-driven opportunities are arising to discover new roles for old medicines and help patients in unexpected ways.
From initial discovery to market-ready product, biotech development is a complex multi-phase process, where strategic partnerships, continuous innovation and careful navigation of regulatory landscapes are crucial for long-term success. Despite this complexity (or perhaps because of it), entrepreneurs and VCs seldom take a step back to consider the full trajectory of this journey. In this article, we’ll explore the typical life cycle of a biotech startup, examining the key milestones and hurdles encountered along the way.
Like two sides of the same coin, industry and academia are each aiming to progress science. On their own, they accomplish great results, but only together can they really drive innovation. One way to reap the fruits from this partnership are endowed chairs. By exchanging resources and independence for publicity and innovative insights, both can contribute to a happier and healthier society.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company’s groundbreaking bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications. This represents an important step forward in the evolution of regenerative medicine, with a particular focus on women’s health.
In the space of just a few years, MRM Health has transformed from a challenger in the emerging microbiome therapeutics field to a global forerunner. CEO Sam Possemiers has steered the Belgian company through the rollercoaster of scientific uncertainty and investor skepticism to reach what he calls the “slope of enlightenment.” Now, with late-stage clinical trials ahead and a new important funding round within reach, Possemiers is sharing his lessons-learned with other biotech CEOs.
European biotech is braving another turbulent cycle. IPOs remain scarce, M&A sluggish, and the lack of liquidity is leaving both innovators and Venture Capitalists struggling to raise funds. But new solutions—including stronger secondary markets—could help restore momentum and build a more resilient, thriving European ecosystem.
Just as European biotech began its post-COVID rebound, it now finds itself grappling with a fresh set of global challenges. The re-election of Donald Trump and his ‘America First’ agenda, alongside mounting economic uncertainty and geopolitical shifts have all sent shockwaves through the industry. With shifting capital flows, upended regulatory expectations, and deep insecurity among biotech entrepreneurs, VCs and LPs, we ask: can Europe turn these lemons into lemonade?
A fresh chapter in Flemish healthtech and life sciences has begun with the launch of Biovia: the health innovation cluster resulting from the merger of flanders.bio and MEDVIA. Unveiled at Knowledge for Growth, the flagship annual conference of the Flemish life sciences sector, this new industry-driven organization brings more than 450 members together in one unified ecosystem – cultivating connections and forging a path to a healthier future for people and planet.
The biotechnology sector has always been characterized by long, uncertain timelines. But with increasing scientific, regulatory, and market complexities, biotech development is now taking longer and costing more than ever before. Investors are being faced with a growing gap between initial investment and successful exit, and it’s vital for entrepreneurs to know how to handle this shift.
Drug repurposing describes the process where drugs originally designed for one condition turn out to be highly effective for another. Historically, drug repurposing has often occurred by chance. However, in the era of big data and artificial intelligence, new data-driven opportunities are arising to discover new roles for old medicines and help patients in unexpected ways.
From initial discovery to market-ready product, biotech development is a complex multi-phase process, where strategic partnerships, continuous innovation and careful navigation of regulatory landscapes are crucial for long-term success. Despite this complexity (or perhaps because of it), entrepreneurs and VCs seldom take a step back to consider the full trajectory of this journey. In this article, we’ll explore the typical life cycle of a biotech startup, examining the key milestones and hurdles encountered along the way.
Like two sides of the same coin, industry and academia are each aiming to progress science. On their own, they accomplish great results, but only together can they really drive innovation. One way to reap the fruits from this partnership are endowed chairs. By exchanging resources and independence for publicity and innovative insights, both can contribute to a happier and healthier society.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company’s groundbreaking bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications. This represents an important step forward in the evolution of regenerative medicine, with a particular focus on women’s health.